MedPath

A clinical trial to study the effects of two drugs Olmesartan and metoprolol in patients with high blood pressure and heart disease

Phase 4
Completed
Conditions
Health Condition 1: null- Hypertension with Cardiovascular Disease
Registration Number
CTRI/2010/091/001438
Lead Sponsor
Glenmark Pharmaceuticals Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
1000
Inclusion Criteria

?All CVD patients (prior MI, ACS, PCI, CABG) with hypertension

OR

?All CVD patients (prior MI, ACS, PCI, CABG) with Uncontrolled hypertension (BP > 140/90 mmHg for hypertensive patients and BP > 130/80 mmHg for hypertensive patients with Diabetes or renal disease).

Exclusion Criteria

?Not willing to provide written informed consent and comply with the protocol
?Age below 18 years and above 65 years
?Secondary hypertension
?Patients requiring concomitant anti-hypertensive medications other than angiotensin receptor blockers (ARBs) or Metoprolol
?Uncontrolled diabetes mellitus
?Baseline laboratory values outside the clinically acceptable limits
?Pregnant women and lactating mothers
?Females of child bearing age not practicing contraception or not willing to use barrier contraceptive
?Known hypersensitivity to Olmesartan/Metoprolol
?Patients with effort angina more than class II (Drugs like Nitrates, ranolazine or Trimetazidine can be used but not amlodipine or nicorandil).
?Sick sinus syndrome or Atrioventricular block or Heart Failure

Study & Design

Study Type
PMS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath